CD-NP (Cenderitide) Therapy for the Preservation of Left Ventricular Function

Summary

The primary endpoint is to assess the safety and tolerability of Cenderitide (CD-NP) with the incidence of symptomatic hypotension being one of the key safety variables.

Timeline

Start

2013-10

Primary completion

2018-05

Completion

2018-11

Drugs

Indications